Molecular Devices Corp.
This article was originally published in The Gray Sheet
Executive SummarySecondary offering of $150 mil. in common stock is outlined in a filing with the Securities and Exchange Commission, including shares to be offered by the company and selling shareholders. Underwriters for the offering include ING Barings, Bear Stearns, Thomas Weisel Partners and Warburg Dillon Read. The Sunnyvale, California firm launched two high throughput microplate readers for use in drug discovery and life science research March 6, including the Spectramax Gemini XS fluorescence microplate reader and Plus384 absorbance microplate reader
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.